New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
16:00 EDTNAVBNavidea reduces R&D expense to less than $20M for 2014
In a regulatory filing, Navidea Biopharmaceuticals disclosed that on June 16, in a conference call, Dr. Michael Goldberg, Interim CEO of Navidea Biopharmaceuticals, stated that, as a result of the previously announced reorganization plan to reduce the company’s cash burn, the company’s previous 2014 research and development expense guidance of between $25M to $30M is being reduced to less than $20M for the calendar year.
News For NAVB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
07:33 EDTNAVBNavidea announces dual listing on Tel Aviv Stock Exchange
Navidea Biopharmaceuticals announced that the Tel Aviv Stock Exchange has approved the new listing of Navidea's common stock on the TASE beginning on Tuesday, September 8 under the ticker symbol NAVB. The company's common stock will be listed on both the NYSE MKT in the United States and the TASE in Israel. The company also announced that, based upon Navidea's current market capitalization, it expects its shares to be subject to inclusion in five TASE equity indexes.
07:27 EDTNAVBSidoti to hold a conference
2015 Sidoti Emerging Growth Conference is being held in New York on September 2.
August 24, 2015
07:32 EDTNAVBNavidea to register shares for dual listing on TASE
Navidea Biopharmaceuticals announced that it has filed an application for registration of shares of its common stock for dual listing on the Tel-Aviv Stock Exchange, or TASE. Dual listing on the TASE is allowed in the U.S. and Israel without any additional regulatory requirements for companies whose shares are listed on certain accredited stock exchanges outside of Israel, including the NYSE MKT.
August 20, 2015
07:31 EDTNAVBNavidea reports publication of Lymphoseek comparative results in pain study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use